ADC Therapeutics SA Stock Prediction
AI-powered sentiment analysis and prediction trends for ADCT, updated each market day.
ADCT AI Sentiment
AI sees no strong directional signal for ADC Therapeutics SA stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Sector
Exchange
Market Cap
$477,686,778
Cap Tier
Employees
193
Headquarters
EPALINGES, V8
Listed Since
May 15, 2020
Website
ADCT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ADCT Volatility
ADC Therapeutics SA has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
